2021 Autumn Conference – Includes Joint Day with ECNP
Applications of Lessons Learned from 2020
30 September – 02 October, 2021 // Virtual Conference
Distinguished Poster Award Recipient:
|
|||
Placebo Response Propensity Scale (PRPS) scores and probability of placebo response by disease severity (Morlock) | |||
View all Poster PDFs and Abstracts |
|||
30 September 2021 |
|||
Welcome from the President | Ramy Mahmoud![]() ![]() |
||
Session 1: Applications of Lessons Learned from 2020: Diversity in CNS clinical trials | Chairs: Carla Canuso Jerry Sanacora H. Lynn Starr |
||
Introduction | Carla Canuso![]() ![]() |
||
Why is diversity in clinical trials important? | David Henderson![]() ![]() |
||
How are we doing? One company’s assessment of diversity in clinical trials | H. Lynn Starr![]() ![]() |
||
Putting new learnings and best practices into action | Lionel Phillips![]() ![]() |
||
The Yale model and our partnered approach: Increasing clinical trial representation through community collaboration and innovation | Tesheia Harris![]() ![]() |
||
Cultural adaptation frameworks and use of real world evidence in the study of diverse populations | Shanaya Rathod![]() ![]() |
||
Recruitment and enrollment panel discussion | Moderators: Carla Canuso Jerry Sanacora ![]() |
||
FDA OMHHE: Working to advance racial and ethnic minority participation in clinical trials | Richardae Araojo![]() ![]() |
||
Statistical approaches under heterogeneous treatment effects | Mark Rothmann![]() ![]() |
||
EMA Regulatory comment | Florence Butlen-Ducuing![]() ![]() |
||
Discussion | Regulatory speakers![]() |
||
Session Summary | Jerry Sanacora Carla Canuso ![]() |
||
Poster Session |
Poster PDFs and Abstracts | ||
1 October 2021 |
|||
Welcome from the Presidents | Gitte Knudsen Ramy Mahmoud ![]() ![]() |
||
Session 2: Knowledge of COVID-19 biology / syndromes: How does it lead to new research considerations | Chairs: David Baldwin Kemi Olugemo |
||
Introduction | Kemi Olugemo![]() ![]() |
||
COVID-19 and mental health: A global perspective | Christoph Correll*![]() ![]() |
||
Nature and course of psychological symptoms in the general population during the pandemic: Insights from national cross-sectional and longitudinal studies | Samuel Chamberlain* |
||
6-month neurological and psychiatric outcomes in 236,379 survivors of COVID-19: A retrospective cohort study using electronic health records | Maxime Taquet ![]() ![]() |
||
Early effects of the pandemic on individuals with serious mental illness: Findings from multisite Ecological Momentary Assessment (EMA) studies | Raeanne Moore![]() ![]() |
||
Panel discussion: Includes patient advocacy perspective | Discussant: Erik Van der Eycken ![]() |
||
Challenges for trial design and analysis during the pandemic era: Development of the CONSERVE statement | Richard Emsley![]() ![]() |
||
Discussion – DeMartinis and Emsley | ![]() |
||
Session Summary | Kemi Olugemo![]() |
||
Session 3: Lessons learned for the good – Overcoming obstacles | Chairs: Dragana Bugarski-Kirola Gerard Dawson |
||
Introduction | Gerard Dawson![]() ![]() |
||
COVID-19 lockdown conditions and depression assessment data from an exploratory MDD clinical trial | Nicholas DeMartinis![]() ![]() |
||
Panel: Impact of COVID-19 pandemic on participants, operational aspects of clinical conduct and implication for data analysis | |||
Introduction | Dragana Bugarski-Kirola![]() |
||
Impact of COVID-19 pandemic on Seriously Mentally Ill (SMI) subjects in clinical trials | Robert Litman![]() ![]() |
||
Case study of an Alzheimer’s disease (AD) international trial successfully initiated during the first wave of the COVID pandemic | Joanne Bell![]() ![]() |
||
Clinical trial continuity in the wake of a pandemic | Ramzey Odetalla![]() ![]() |
||
Conducting a pediatric orphan (Tourette’s study pre & during COVID shutdown: Experience and lessons learned | Atul Mahableshwarkar![]() ![]() |
||
Panel Discussion | Facilitator: Gerard Dawson ![]() |
||
Impact of COVID-19 lockdown on data integrity and analysis of a transdiagnostic study with two patient populations | Dennis Hernaus![]() ![]() |
||
Panel: Regulatory discussants | Discussants:![]() Valentina Mantua ![]() ![]() Lorenzo Guizzaro ![]() ![]() |
||
Panel Discussion | All speakers![]() |
||
Session Summary | Gerard Dawson![]() |
||
2 October 2021 |
|||
Saturday Concurrent Working Group Sessions |
|||
Innovative technologies for CNS clinical trials | Chairs: Richard Keefe Michael Davis |
||
Joint ISCTM/ECNP COVID-19 methodologies blueprint | Chairs: Dragana Bugarski-Kirola Gerard Dawson Kemi Olugemo |
||
Orphan diseases | Chairs: Joan Busner Gahan Pandina |
||
*Full presentation not released |